Found: 8
Select item for more details and to access through your institution.
Different cutoffs definitions to evaluate the concordance between CSF Ab42 and Ab42/Ab40 across neurodegenerative diseases.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2023, v. 19, p. 1, doi. 10.1002/alz.064134
- By:
- Publication type:
- Article
Plasma biomarkers for the AT(N) classification and for the detection of Alzheimer's disease.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2021, v. 17, p. 1, doi. 10.1002/alz.050187
- By:
- Publication type:
- Article
APP‐derived peptides reflect neurodegeneration in frontotemporal dementia.
- Published in:
- Annals of Clinical & Translational Neurology, 2019, v. 6, n. 12, p. 2518, doi. 10.1002/acn3.50948
- By:
- Publication type:
- Article
The Sant Pau Initiative on Neurodegeneration (SPIN) cohort: A data set for biomarker discovery and validation in neurodegenerative disorders.
- Published in:
- Alzheimer's & Dementia: Translational Research & Clinical Interventions, 2019, v. 5, n. 1, p. 597, doi. 10.1016/j.trci.2019.09.005
- By:
- Publication type:
- Article
Correction: Plasma glial fibrillary acidic protein and neurofilament light chain for the diagnostic and prognostic evaluation of frontotemporal dementia.
- Published in:
- 2023
- By:
- Publication type:
- Correction Notice
Plasma glial fibrillary acidic protein and neurofilament light chain for the diagnostic and prognostic evaluation of frontotemporal dementia.
- Published in:
- Translational Neurodegeneration, 2021, v. 10, n. 1, p. 1, doi. 10.1186/s40035-021-00275-w
- By:
- Publication type:
- Article
Plasma glial fibrillary acidic protein and neurofilament light chain for the diagnostic and prognostic evaluation of frontotemporal dementia.
- Published in:
- Translational Neurodegeneration, 2021, v. 10, n. 1, p. 1, doi. 10.1186/s40035-021-00275-w
- By:
- Publication type:
- Article
The Aβ1–42/Aβ1–40 ratio in CSF is more strongly associated to tau markers and clinical progression than Aβ1–42 alone.
- Published in:
- Alzheimer's Research & Therapy, 2022, v. 14, n. 1, p. 1, doi. 10.1186/s13195-022-00967-z
- By:
- Publication type:
- Article